ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences:
Investors who wish to request a meeting should contact their sales representative at the sponsoring firms or reach out to electroCore Investor Relations at investors@electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

| Nov-12 | |
| Nov-05 | |
| Nov-04 | |
| Nov-04 | |
| Oct-29 | |
| Oct-29 | |
| Oct-28 | |
| Oct-27 | |
| Oct-21 | |
| Sep-10 | |
| Sep-09 | |
| Aug-25 | |
| Aug-06 | |
| Aug-03 | |
| Jul-30 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite